ACADIA Pharmaceuticals Inc. (ACAD) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

22/25

Growth 5 Margin 5 Expansion 5 Platform 3 Financial 4

latest quarter score

Earnings Reports

22
Acadia Pharmaceuticals (ACAD) Q2 2026: Debut Stix Drives 30% Growth as EU Launch Nears
August 05, 2026
18
Acadia Pharmaceuticals (ACAD) Q1 2026: Debut Sticks Drives 20% Growth, Pipeline Readouts Set $11B Opportunity in Motion
May 07, 2026
15
Acadia Pharmaceuticals (ACAD) Q4 2025: New Plazid Prescriber Base Expands 40% as Field Force Grows
February 26, 2026
21
Acadia Pharmaceuticals (ACAD) Q3 2025: Nuplazid Sales Jump 12% as Field Force Expansion Accelerates Growth
November 12, 2025
18
Acadia Pharmaceuticals (ACAD) Q2 2025: 14% Growth in DAYBUE Reflects Commercial Expansion and Pipeline Momentum
August 06, 2025
18
Acadia (ACAD) Q1 2025: Daybue Patient Base Rises to 954, Persistency Surpasses 65% Beyond Year One
July 04, 2025
Acadia Pharmaceuticals (ACAD) Q3 2024: Debut Patient Persistence Tops 60%, Underpinning Durable Rare Disease Growth
November 06, 2024
Acadia Pharmaceuticals (ACAD) Q2 2024: Nuplazid Guidance Raised $30M as DTC Campaigns Target Underpenetrated Markets
August 06, 2024
Acadia Pharmaceuticals (ACAD) Q1 2024: Debut Drives 74% Revenue Surge as Persistency Tops Clinical Benchmarks
May 08, 2024
Acadia Pharmaceuticals (ACAD) Q4 2023: Debut Drives 69% Revenue Surge, Expanding Rare Disease Platform
February 27, 2024
21
Acadia Pharmaceuticals (ACAD) Q3 2023: Debut Launch Drives 81% Four-Month Persistency, Reshaping Rare Disease Penetration Curve
November 02, 2023
Acadia Pharmaceuticals (ACAD) Q2 2023: Debut Launch Drives $23M in First Quarter, Setting Rare Disease Franchise Trajectory
August 02, 2023
Acadia (ACAD) Q1 2023: Debut Launch Targets 4,500 Rett Patients, Unlocks Rare Disease Growth Path
May 08, 2023
Inari Medical (NARI) Q4 2022: International Revenue Jumps 144% as Market Expansion Accelerates
February 27, 2023

Browse all companies